MedTrace Logo

Doxapram Administration on Diaphragmatic Excursion in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease Undergoing Spontaneous Breathing Trial

NCT07022704 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2025-06-26

No results posted yet for this study

Summary

Researchers aim to evaluate the impact of doxapram administration on diaphragmatic excursion in chronic obstructive pulmonary disease (COPD) patients undergoing spontaneous breathing trial

Conditions

  • COPD
  • Mechanical Ventilation
  • Weaning From Mechanical Ventilation

Interventions

DRUG

Doxapram

Doxapram will be given as 1.5 mg/kg will be given 10 minutes after the initiation of SBT

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-22
Primary Completion
2025-10-30
Completion
2025-11-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07022704 on ClinicalTrials.gov